IGC Pharma, Inc.
IGC · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -41.8% | -0.6% | 28.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 51.8% | 47% | 46.7% | 40.5% |
| R&D Expenses | $2 | $1 | $1 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3 | $2 | $2 | $2 |
| Operating Income | -$3 | -$2 | -$1 | -$2 |
| % Margin | -1,517.8% | -580.8% | -427.9% | -730.7% |
| Other Income/Exp. Net | $1 | $0 | $0 | $0 |
| Pre-Tax Income | -$2 | -$2 | -$1 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$2 | -$1 | -$2 |
| % Margin | -953.4% | -487.5% | -362.7% | -711.7% |
| EPS | -0.02 | -0.019 | -0.016 | -0.024 |
| % Growth | -3.6% | -23.7% | 33.9% | – |
| EPS Diluted | -0.02 | -0.019 | -0.016 | -0.024 |
| Weighted Avg Shares Out | 90 | 83 | 77 | 78 |
| Weighted Avg Shares Out Dil | 90 | 83 | 77 | 78 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$2 | -$1 | -$2 |
| % Margin | -891.1% | -537.8% | -381.2% | -669.6% |